CNS disorders--current treatment options and the prospects for advanced therapies

Drug Development and Industrial Pharmacy
James C DiNunzio, Robert O Williams

Abstract

The development of new pharmaceutical products has successfully addressed a multitude of disease states; however, new product development for treating disorders of the central nervous system (CNS) has lagged behind other therapeutic areas. This is due to several factors including the complexity of the diseases and the lack of technologies for delivery through the blood-brain barrier (BBB). This article examines the current state of six major CNS disease states: depression, epilepsy, multiple sclerosis (MS), neurodegenerative diseases (specifically Alzheimer's disease [AD]), neuropathic pain, and schizophrenia. Discussion topics include analysis of the biological mechanisms underlying each disease, currently approved products, and available animal models for development of new therapeutic agents. Analysis of currently approved therapies shows that all products depend on the molecular properties of the drug or prodrug to penetrate the BBB. Novel technologies, capable of enhancing BBB permeation, are also discussed relative to improving CNS therapies for these disease states.

References

Jan 1, 1988·The British Journal of Psychiatry : the Journal of Mental Science·R W Kerwin
Sep 1, 1987·The British Journal of Psychiatry : the Journal of Mental Science·P J McKenna
Jul 1, 1987·Archives of General Psychiatry·D R Weinberger
Apr 1, 1972·European Journal of Pharmacology·J P HanigS Krop
Jan 1, 1995·Neuroscience and Biobehavioral Reviews·F Borsini
May 15, 1996·European Journal of Pharmacology·C ToberR Bartsch
Sep 1, 1996·Postgraduate Medical Journal·R GuleriaL Prasad
Mar 27, 1997·Biochemical and Biophysical Research Communications·S YokoyamaK Yagi
Oct 10, 1998·The Journal of Membrane Biology·H FischerA Seelig
Nov 5, 1998·Journal of Controlled Release : Official Journal of the Controlled Release Society·J ChopineauD Domurado
Jan 21, 2000·Journal of Controlled Release : Official Journal of the Controlled Release Society·U Conte, L Maggi
Jan 29, 2000·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·C López-Rubalcava, I Lucki
Feb 5, 2000·The New England Journal of Medicine·P Kwan, M J Brodie
Jun 7, 2000·Proceedings of the National Academy of Sciences of the United States of America·N Shi, W M Pardridge
May 19, 2001·Neurologic Clinics·S R Benbadis
May 24, 2001·Proceedings of the National Academy of Sciences of the United States of America·T SugawaraK Yamakawa
May 24, 2001·Current Opinion in Neurology·R Hohlfeld, H Wekerle
Oct 11, 2001·Proceedings of the National Academy of Sciences of the United States of America·N ShiW M Pardridge
Jan 16, 2002·Archives of Neurology·William M Pardridge
Jan 16, 2002·Drug Discovery Today·William M Pardridge

❮ Previous
Next ❯

Citations

Apr 26, 2012·BMC Complementary and Alternative Medicine·Jun RenJian-You Guo
Feb 3, 2012·Biomarkers in Medicine·Hong I WanJeffrey F Waring
Oct 29, 2015·Molecular Membrane Biology·Dhaval PatelMukesh Nandave
Jan 11, 2011·Drug Development and Industrial Pharmacy·S MartinsM Brandl
Jun 1, 2014·Journal of Controlled Release : Official Journal of the Controlled Release Society·Irja Elliott DonaghueMolly S Shoichet
Mar 22, 2012·Medicinal Research Reviews·Patrick Vlieghe, Michel Khrestchatisky
Dec 12, 2013·Chemical Biology & Drug Design·Jocelyn StockwellChangiz Taghibiglou
Mar 4, 2014·Bioorganic & Medicinal Chemistry Letters·Dwight A WilliamsYan Zhang
Nov 28, 2013·ACS Chemical Neuroscience·Leyuan XuYue Wu
Nov 12, 2014·PloS One·Daniel Cesar Silva da CostaCláudia Maria Valete-Rosalino
Oct 31, 2014·PLoS Neglected Tropical Diseases·Joseph A LewnardDaniel M Weinberger
Mar 17, 2011·PLoS Neglected Tropical Diseases·Jorge Augusto de Oliveira GuerraLuiz Carlos de Lima Ferreira
Jan 26, 2018·Biomaterials Science·Emanuele MauriStefano Pluchino
Apr 4, 2019·Molecular Neurobiology·Eliana Baez-JuradoGeorge E Barreto
Jul 25, 2019·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Heather BranscomeFatah Kashanchi
Dec 15, 2016·Micromachines·Giovanni Stefano UgoliniMarco Rasponi
May 30, 2020·International Journal of Molecular Sciences·Giordano PeriniMassimiliano Papi
Nov 23, 2021·Nanomedicine·Anisha A D'SouzaMansoor M Amiji

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

Antiparasitics

Antiparasitics are medications which are indicated for the treatment of parasitic diseases. Discover the latest research on antiparasitics here.

© 2022 Meta ULC. All rights reserved